NXL:NASDAQ, Nexalin Technology, Inc.
NXL stock overview
Nexalin Technology, Inc. (NXL:NASDAQ) closed at $1.51 on November 2, 2026,
down 5.94% on the day.
The stock trades 96.7% below its 52-week high of $45.00
and 6.7% above its 52-week low of $1.41.
Over the past year, it lost 96.4%.
Nexalin Technology, Inc. is part of the Health Care sector.
Key figures
- Price
- $1.51
- Day change
- -5.94%
- Volume
- 11,860
- Average volume
- 1,033,275
- Market cap
- 1M+
- 52-week range
- $1.41 – $45.00
- 50-day average
- $4.61
- 200-day average
- $10.90
Price action over the past year
In 252 trading sessions since October 31, 2025, NXL closed higher on 90 days (36%).
Its best day was October 1, 2026 (+76.40%) and its worst was July 28, 2026 (-24.21%).
The stock moved 10% or more in a single session 27 times.
It opened at least 5% above the previous day's high 4 times.
Recent signals
NXL news
-
Oct 27, 2026:
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
-
Oct 27, 2026:
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
-
Oct 8, 2026:
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
-
Oct 1, 2026:
Top Midday Gainers
-
Oct 1, 2026:
Nexalin Technology Signs South America Distribution Agreement for Nexalin Sync Commercialization
-
Oct 1, 2026:
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
-
Sep 29, 2026:
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
-
Sep 11, 2026:
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
About Nexalin Technology, Inc.
Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.
Similar stocks
Find more stocks like NXL with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.